CTAP101

DRUG2 trials

Sponsors

OPKO Health, Inc.

Conditions

CKD Stage 3CKD Stage 4Chronic Kidney Disease stage3Chronic Kidney Disease stage4Secondary HyperparathyroidismVDIVitamin d Deficiency

Phase 2

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release Capsules in Pediatric Participants

RecruitingNCT07494045

OPKO Health, Inc.CKD Stage 3, CKD Stage 4, Secondary Hyperparathyroidism +1

Start: 2026-08-05End: 2028-08-01Target: 40Updated: 2026-08-20

Phase 3

Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary Hyperparathyroidism

TerminatedNCT05543928

OPKO Health, Inc.Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Secondary Hyperparathyroidism +1

Start: 2023-01-31End: 2024-06-19Updated: 2025-07-25